| Literature DB >> 28208818 |
Oludemi Taofiq1,2,3, Ana M González-Paramás4, Maria Filomena Barreiro3, Isabel C F R Ferreira5.
Abstract
Bioactive compounds from natural sources, due to their widely-recognized benefits, have been exploited as cosmeceutical ingredients. Among them, phenolic acids emerge with a very interesting potential. In this context, this review analyzes hydroxycinnamic acids and their derivatives as multifunctional ingredients for topical application, as well as the limitations associated with their use in cosmetic formulations. Hydroxycinnamic acids and their derivatives display antioxidant, anti-collagenase, anti-inflammatory, antimicrobial and anti-tyrosinase activities, as well as ultraviolet (UV) protective effects, suggesting that they can be exploited as anti-aging and anti-inflammatory agents, preservatives and hyperpigmentation-correcting ingredients. Due to their poor stability, easy degradation and oxidation, microencapsulation techniques have been employed for topical application, preventing them from degradation and enabling a sustained release. Based on the above findings, hydroxycinnamic acids present high cosmetic potential, but studies addressing the validation of their benefits in cosmetic formulations are still scarce. Furthermore, studies dealing with skin permeation are scarcely available and need to be conducted in order to predict the topical bioavailability of these compounds after application.Entities:
Keywords: cosmetics; hydroxycinnamic acids; microencapsulation; skin care
Mesh:
Substances:
Year: 2017 PMID: 28208818 PMCID: PMC6155946 DOI: 10.3390/molecules22020281
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Schematic representation of hydroxycinnamic acid synthesis.
Figure 2Hydroxycinnamic acids and their derivatives.
Anti-aging and anti-tyrosinase activities reported for hydroxycinnamic acids and their derivatives.
| Compound | Source | Bioactivity | Effects | Reference |
|---|---|---|---|---|
| Ascorbyl-3- | Commercial | Antityrosinase | At 100 µM, decreased melanin content by 65% and 59%, respectively. | [ |
| Ascorbyl-3- | Commercial | Anti-collagenase | At 100–300 µM, they promoted collagen release by 120%–144% and 125%–191%, respectively. | [ |
| Caffeoyl-amino acidyl-hydroxamic acid | Synthesized | Antityrosinase | At 100 μM, displayed anti-tyrosinase activity. | [ |
| Caffeic acid oligomers | Anti-hyaluronidase | From 19–1000 μM, compounds showed up to 50% anti-hyaluronidase activity. | [ | |
| Chlorogenic acid | Commercial | Antityrosinase | At 500 μM after 48-h exposure to B16 melanoma cells, melanin levels were suppressed. | [ |
| Dietary phenolic acids | Commercial | Antityrosinase | [ | |
| Dietary phenolic acids | Commercial | Antityrosinase | Caffeic acid 24.1 + 6.2 and ferulic acid >30 μM caused 30% inhibition f tyrosinase. | [ |
| Ferulic and caffeic acids | Commercial | Anti-collagenase | Ferulic (15–30 µM) and caffeic (3.75–30 µM) suppressed UVA-induced MMP-1 activity. | [ |
| Ferulic and caffeic acids | Commercial | Photoprotection | Both compounds at 200 µL offered protective activity to UVB-induced skin erythema. | [ |
| Ferulic acid | Commercial | Anti-collagenase | FA applied topically at 0.01, 0.05–1 mg/site/mouse, significantly suppressed the expression of MMP-2 and MMP-9. | [ |
| Hydroxycinnamic amides | Synthesized | Antityrosinase | At 0.185–475 µM, all nine derivatives significantly inhibited tyrosinase activity up to 50%. | [ |
| Synthesized | Antityrosinase | All investigated amides significantly inhibited tyrosinase activity. | [ | |
| Commercial | Antityrosinase | At 10 µg/mL, showed a higher tyrosinase activity inhibition than arbutin, but comparable to kojic acid. | [ | |
| Antityrosinase | Reduced MITF and tyrosinase mRNA expression by 73% and 82%, respectively. | [ | ||
| Commercial | Antityrosinase | Inhibited hyperpigmentation up to 77% in human skin. | [ | |
| Commercial | Anti-collagenase | At 30 µg/mL, inhibited MMP-1 expression from dermal fibroblasts. | [ | |
| Commercial | Antityrosinase | [ | ||
| Rosmarinic acid | Antityrosinase | At 10 μM, tyrosinase activity was inhibited by 20%. | [ | |
| Rosmarinic acid | Photoprotection | At 0.9–18 mg/L, UVA-induced changes in human keratinocytes cells were suppressed. | [ | |
| Photoprotection | Oral administration of rosmarinic acid suppressed cutaneous alterations in vivo due to UVA exposure. | [ | ||
| Rosmarinic acid derivatives | Anti-hyaluronidase | Between 183 and 1049 μM, compounds showed up to 50% anti-hyaluronidase activity. | [ | |
| Rosmarinic acid, methyl rosmarinate | Antityrosinase | At 0.4 mM, rosmarinic acid and methyl rosmarinate inhibited tyrosinase activity by 19.80% and 37.10% respectively. | [ | |
| Rosmarinic acid methyl ester | Antityrosinase | At 20 μg/mL, the expression of MITF, tyrosinase, TRP-2 and TRP-1 was downregulated. | [ |
MMP-1: matrix metalloproteinase-1, MMP-2: matrix metalloproteinase-2, MMP-9: matrix metalloproteinase-9, MITF: microphthalmia-associated transcription factor, TRP-1: tyrosinase-related protein-1, TRP-2: tyrosinase-related protein-2.
Anti-inflammatory activity reported for hydroxycinnamic acids and their derivatives.
| Compound | Source | Effect | Reference |
|---|---|---|---|
| 1- | Up to 400 µM suppressed TNF-α and IL-1β levels, reduced iNOS and COX-2 expression and inhibited Iκβ degradation. | [ | |
| 3,4,5-Trihydroxycinnamic acid | Commercial | At 100 µM, it suppressed NO production up to 70% and reduced Iκβ degradation. | [ |
| Acetyl-caffeic acid–1-piperonylpiperazine | Synthesized | At 20 μM, up to 60%–70% of NO was suppressed and NF-κβ activation inhibited. | [ |
| Caffeic acid | Commercial | At 10–200 μg/mL, IL-8, IL-1β, IL-6 and TNF-α levels were suppressed, IκBα degradation and p65 phosphorylation inhibited. | [ |
| Commercial | At 10 μg/mL, it suppressed NO levels, blocked NF-κβ translocation and prevented IκB-α degradation. | [ | |
| Caffeic acid phenethyl ester (CAPE) | Commercial | At 1 µM, COX-1 and IL-1β expression was suppressed. | [ |
| Caffeic acid derivatives (methyl, ethyl, butyl) | Commercial | At 21.4, 11.9 and 8.4 µM, the derivatives inhibited NO levels up to 50%. | [ |
| Caffeic acid methyl vanillate ester | Synthesized | At 15 μM, it suppressed NO levels and inhibited TNF-α, COX-2 and ICAM-1 expression. | [ |
| Chlorogenic acid | Commercial | 0.5–100 μmol/L of CGA suppressed the expression of NF‑κB, p50 and IKKα/β. | [ |
| Commercial | Intraperitoneally at 2.5–50 mg/kg, it suppressed TNF-α, IL-1β and IL-6 release by inhibiting the TLR4-mediated NF-κβ signaling pathway. | [ | |
| Commercial | At 20 μM, levels NO, IL-1β, TNF-α and IL-6 were suppressed and the expression of COX-2 and iNOS reduced. | [ | |
| At 140 μg/mL, the level of NO was significantly suppressed. | [ | ||
| Commercial | Up to 20 μM of CGA reduced the expression of IL-1β and COX-2. | [ | |
| Cinnamic acid, glucuronated and methylated derivatives | Synthesized | NO levels were suppressed significantly at 224 ± 16 μM. | [ |
| Ferulic | Commercial | FA topically and intraperitoneally inhibited the expression of TNF-α and IL-6. | [ |
| Hydroxycinnamic amides | Corn bran | All four amides evaluated inhibited NO level and dose-dependently suppressed iNOS expression. | [ |
| Synthesized | NO levels were suppressed significantly at 442 ± 33 μM. | [ | |
| Up to 40 µM suppressed TNF-α, NO, PGE2, IL-1β, iNOS and COX-2 expression and prevented JNK/c-Jun and Akt phosphorylation. | [ | ||
| Commercial | Suppressed TNF-α levels in vivo at 100 mg/kg body weight in arthritis-induced rats. | [ | |
| Rosmarinic acid | At 36.03 µg/mL, TNF-α levels were inhibited up to 36.75% ± 1.55%, and MAPK was inhibited up to 50% at 1.16 ± 0.13 µg/mL. | [ | |
| Commercial | At 2.75 μM expression of IL-6 and IL-8 was suppressed. | [ | |
| Commercial | At 1 µg/mL, TNF-α levels were reduced and iNOS expression suppressed. | [ | |
| At 2.67 μM, PGE2 and NO production was inhibited by 15% and 17%, respectively. | [ | ||
| Commercial | TNF- α, IL-6 and IL-1β levels were suppressed after administration of 5, 10 and 20 mg/kg of rosmarinic acid/mice weight. | [ | |
| At 66 μg/mL, PGE2 production was suppressed by 72% | [ | ||
| Trans-caffeic acid | At 100 mg/kg, it suppressed carrageen-induced paw edema in rat by 50% | [ |
COX-2: cyclooxygenase-2, ICAM-1: intercellular adhesion molecule-1, IKK: Iκβ kinase, IL-1β: interleukin 1β, IL-6: interleukin 6, IL-8: interleukin 8, iNOS: inducible nitric oxide synthase, MAPK: mitogen-activated protein kinase, NF-κβ: nuclear factor-κB, NO: nitric oxide, PGE2: prostaglandin E2, TLR4: Toll-like receptor 4, TNF-α: tumor necrosis factor α.
Antimicrobial activity reported for hydroxycinnamic acids and their derivatives.
| Compound | Source | Microorganism | Effect | Reference |
|---|---|---|---|---|
| 2-Coumaric acid | Synthesized | MIC value of 122 µM | [ | |
| 3,4-Dialkoxy caffeic acids | Synthesized | GI 100 μg/mL | [ | |
| 5- | 2.7–6.3 mg/mL | [ | ||
| Commercial | MIC 5–10 mg/mL | [ | ||
| Caffeic and cinnamic acid ester | Synthesized | MIC 32 µg/mL | [ | |
| Caffeic, chlorogenic, | Commercial | MIC 125–1000 μg/mL | [ | |
| Caffeoylquinic acids | MIC 32–256 μg/mL | [ | ||
| Caffeoylquinic acids | Prunus mume seeds | MIC 10–250 μg/mL | [ | |
| Chlorogenic acid | Synthesized | MIC 20–80 μg/mL | [ | |
| Chlorogenic, rosmarinic, sinapic and ferulic acid | Commercial | MIC 4.9–313 μg/mL | [ | |
| Ferulic acid | MIC 28.1–149.7 μg/mL | [ | ||
| Commercial | MBC 500–5000 μg/mL | [ | ||
| Commercial | MIC 500 μg/mL | [ | ||
| Ferulic acid esters | Synthesized | MIC 8–1024 μg/mL | [ | |
| Ferulic acid, | Commercial | MIC 0.01–0.04 mg/mL | [ | |
| Commercial | GI 5.9%–99.9% | [ | ||
| Commercial | MIC 10–80 μg/mL | [ | ||
| Synthesized | MIC 0.68–1.93 μM/mL | [ | ||
| Rosmarinic acid | MIC 1 mg/mL | [ | ||
| MIC 5 µg/mL | [ | |||
| Rosmarinic acid, methyl rosmarinate | MIC 0.3–2.5 mg/mL | [ | ||
| Sinapic acid | MIC 0.2–0.7 g/L | [ | ||
| Trans-cinnamaldehyde, | Commercial | 0.25%–0.5% concentration | [ |
GI: growth inhibitory activity, MBC: minimal bactericidal concentrations, MIC: minimum inhibitory concentration.